

## SSBH 2021 Curriculum Vitae

<b>Name</b>	<b>Aris N. Economides</b>
<b>Organization</b>	<b>Regeneron Pharmaceuticals, Inc.</b>
<b>Position &amp; Title</b>	<b>VP - Research</b>

### **Educational background & Professional experience**

2017-present	Regeneron Pharmaceuticals	VP – Research Cofounder – Regeneron Genetics Center
2015-2016	Regeneron Pharmaceuticals	Executive Director Cofounder – Regeneron Genetics Center
2004-2015	Regeneron Pharmaceuticals	Senior Director
2002-2003	Regeneron Pharmaceuticals	Director
2001-2001	Regeneron Pharmaceuticals	Associate Director
2000-2000	Regeneron Pharmaceuticals	Senior Staff Scientist
1998-2000	Regeneron Pharmaceuticals Rockefeller University	Staff Scientist Visiting Scientist
1996-1997	Regeneron Pharmaceuticals	Scientist
1992-1995	Regeneron Pharmaceuticals	Postdoctoral Fellow
1987-1992	Michigan State University	Graduate Student (Ph.D., Biochemistry)
1986-1987	Dartmouth College	Graduated Student (Biology)
1982-1986	Bennington College	Undergraduate Student (Nat. Sci. & Math)

### **Research Interests**

My research is focused on several different areas: technology development projects in the area of protein therapeutics, the development of biologic as well as genetic therapies for rare diseases, and understanding the molecular mechanisms that drive key phenotypes in both common and rare diseases with the aim of using that information to define new targets and develop corresponding therapies (i.e. what is usually referred as target discovery, validation, and drug development). In addition, I have been deeply involved in the founding of Regeneron Genetics Center, where I currently run a group that is devoted to the biological validation and exploitation of human genetics findings.

### **Publications**

1. Alessi Wolken, D.M., Idone, V., Hatsell, S.J., Yu, P.B., and Economides, A.N. (2018). The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. *Bone* 109, 210-217.
2. Aykul, S., Corpina, R.A., Goebel, E.J., Cunanan, C.J., Dimitriou, A., Kim, H.J., Zhang, Q., Rafique, A., Leidich, R., Wang, X., *et al.* (2020). Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop. *Elife* 9.
3. Dey, D., Bagarova, J., Hatsell, S.J., Armstrong, K.A., Huang, L., Ermann, J., Vonner,

- 
- A.J., Shen, Y., Mohedas, A.H., Lee, A., *et al.* (2016). Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. *Science translational medicine* 8, 366ra163.
4. Goebel, E.J., Corpina, R.A., Hinck, C.S., Czepnik, M., Castonguay, R., Grenha, R., Boisvert, A., Miklossy, G., Fullerton, P.T., Matzuk, M.M., *et al.* (2019). Structural characterization of an activin class ternary receptor complex reveals a third paradigm for receptor specificity. *Proc Natl Acad Sci U S A* 116, 15505-15513.
  5. Hatsell, S.J., Idone, V., Wolken, D.M., Huang, L., Kim, H.J., Wang, L., Wen, X., Nannuru, K.C., Jimenez, J., Xie, L., *et al.* (2015). ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. *Science translational medicine* 7, 303ra137.
  6. Upadhyay, J., Xie, L., Huang, L., Das, N., Stewart, R.C., Lyon, M.C., Palmer, K., Rajamani, S., Graul, C., Lobo, M., *et al.* (2017). The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva is Activin A-Dependent. *J Bone Miner Res.*
-